# Epidiolex® (cannabidiol) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/cannabidiol

> The PDUFA target action date for Epidiolex® (cannabidiol), sponsored by Jazz Pharmaceuticals plc (JAZZ), is April 16, 2027. Status: scheduled.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### When is the Epidiolex® (cannabidiol) PDUFA date?

The PDUFA target action date for Epidiolex® (cannabidiol), sponsored by Jazz Pharmaceuticals plc (JAZZ), is April 16, 2027. Status: scheduled. Press release filed with the SEC (EX-99): "•The PDUFA target action date for our New Drug Application (NDA) for the oral cannabidiol capsule formulation is April 16, 2027." Last confirmed November 2, 2026. [Calendar and source filings](https://sec-api.dev/pdufa/cannabidiol)

Source: Press release filed with the SEC (EX-99), accession 0001232524-26-000056, https://www.sec.gov/Archives/edgar/data/1232524/000123252426000056/a3q26earningsrelease.htm (retrieved 2026-11-12). Last confirmed 2026-11-02. Cite: https://sec-api.dev/pdufa/cannabidiol#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | Epidiolex® (cannabidiol) |
| Codes |  |
| Sponsor | Jazz Pharmaceuticals plc (JAZZ) https://sec-api.dev/companies/jazz/catalysts |
| Indications |  |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Nov 2025: trial start

- Status: completed. Date confidence: month. Stage: 1.
- First seen 2026-02-24, last confirmed 2026-11-02.
- SEC Form 10-Q (accession 0001232524-26-000057): "In November 2025, we initiated a Phase 1b trial evaluating cannabidiol oral solution as an adjunctive treatment in reducing the frequency of focal seizures compared to the baseline as well as the effect of it on health outcome endpoints in early line and refractory participants with focal-onset seizures." https://www.sec.gov/Archives/edgar/data/1232524/000123252426000057/jazz-20260930.htm
- SEC Form 10-Q (accession 0001232524-26-000045): "In November 2025, we initiated a Phase 1b trial evaluating cannabidiol oral solution as an adjunctive treatment in reducing the frequency of focal seizures compared to the baseline as well as the effect of it on health outcome endpoints in early line and refractory participants with focal-onset seizures." https://www.sec.gov/Archives/edgar/data/1232524/000123252426000045/jazz-20260630.htm
- SEC Form 10-Q (accession 0001232524-26-000025): "In November 2025, we initiated a Phase 1b trial evaluating Epidiolex as an adjunctive treatment in reducing the frequency of focal seizures compared to the baseline as well as the effect of Epidiolex on health outcome endpoints in early line and refractory participants with focal-onset seizures." https://www.sec.gov/Archives/edgar/data/1232524/000123252426000025/jazz-20260331.htm
- SEC Form 10-K (accession 0001232524-26-000013): "In November 2025, we initiated a Phase 1b trial evaluating Epidiolex as an adjunctive treatment in reducing the frequency of focal seizures compared to the baseline as well as the effect of Epidiolex on health outcome endpoints in early line and refractory participants with focal-onset seizures." https://www.sec.gov/Archives/edgar/data/1232524/000123252426000013/jazz-20251231.htm

### April 16, 2027: PDUFA date

- Status: scheduled. Date confidence: exact.
- First seen 2026-11-02, last confirmed 2026-11-02.
- Press release filed with the SEC (EX-99) (accession 0001232524-26-000056): "•The PDUFA target action date for our New Drug Application (NDA) for the oral cannabidiol capsule formulation is April 16, 2027." https://www.sec.gov/Archives/edgar/data/1232524/000123252426000056/a3q26earningsrelease.htm
- SEC Form 10-Q (accession 0001232524-26-000057): "FDA accepted the NDA and granted a PDUFA target action date of April 16, 2027." https://www.sec.gov/Archives/edgar/data/1232524/000123252426000057/jazz-20260930.htm

Calendar months: [April 2027](https://sec-api.dev/fda-calendar/2027-04)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/cannabidiol.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Epidiolex® (cannabidiol) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/cannabidiol

```bibtex
@misc{secapidev_pdufa_cannabidiol_20261116,
  title        = {Epidiolex® (cannabidiol) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/cannabidiol}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_cannabidiol_20261116","title":"Epidiolex® (cannabidiol) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/cannabidiol","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
